- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Kornam is a peripheral postsynaptic a1 -adrenoreceptor blocker.
By blocking the a1-adrenoreceptors of the smooth muscles of the prostate gland and the bladder neck, the drug helps to normalize urination in patients with benign prostatic hyperplasia.
It causes the expansion of arterioles and venules, reduces round fistula and venous return to the heart, resulting in a decrease in blood pressure. Onset of hypotensive action 15 minutes after ingestion (single dose). The duration of the hypotensive effect is 24 hours. The maximum effect when taking a single dose is achieved within 2-3 hours. The maximum hypotensive effect is achieved after 6-8 weeks of therapy. With prolonged use, a decrease in blood pressure is not accompanied, as a rule, by the development of reflex tachycardia.
The drug contributes to the normalization of lipid metabolism: reduces the content of cholesterol, TG, LDL and VLDL in the blood, while increasing the number of HDL.
With the systematic use of Kornam, there is regression of left ventricular hypertrophy.
- Benign prostatic hyperplasia (symptomatic treatment).
- Arterial hypertension.
1 tablet contains: terazosin (in the form of hydrochloride dihydrate) 2 mg.
Terazosin is marketed under different brands and generic names, and comes in different dosage forms:
|Brand name||Manufacturer||Country||Dosage form|
No customer reviews for the moment.
Dosage and Administration
With benign prostatic hyperplasia, the initial dose is 1 mg 1 time / day. before bedtime. Gradually, the dose is increased to 2-10 mg / day. to achieve the optimal effect. The therapeutic effect is usually marked 2 weeks after the start of treatment. To achieve a lasting effect, the course of treatment should be 4-6 weeks.
In hypertension, the drug is prescribed in an initial dose of 1 mg / day. before bedtime. Gradually increase the dose to achieve a clinical effect. Maintenance dose is 1-10 mg 1 time / day. The maximum daily dose is 20 mg. In the case of a temporary cessation of the drug, treatment is resumed according to the same scheme.
- In the treatment of benign prostatic hyperplasia
Since the cardiovascular system: rarely - orthostatic hypotension.
CNS: drowsiness, dizziness, asthenia.
Other: nasal congestion.
- In the treatment of hypertension
On the part of the cardiovascular system: orthostatic hypotension - the “first dose effect” (observed in 1% of patients, mostly receiving diuretics or beta-blockers at the same time), manifested by dizziness, tachycardia, fainting; rarely - palpitations, peripheral edema, nasal congestion.
From the side of the central nervous system: rarely - dizziness, asthenia, drowsiness, impaired clarity of visual perception.
On the part of the hematopoietic system: a decrease (associated with hemodilution) of hematocrit, hemoglobin, leukopenia, hypoproteinemia, hypoalbuminemia.
Other: rarely - reduced potency, nausea.
- Hypersensitivity to the drug.
Precautions should be prescribed the drug for angina, coronary heart disease, hepatic or renal failure, cerebrovascular accident, type 1 diabetes mellitus.
With simultaneous use of Kornam and beta-blockers, diuretics, calcium channel blockers, ACE inhibitors, the antihypertensive effect may increase. Special care is required with the simultaneous appointment of terazosin and antihypertensive drugs of central action.
Terazosin absorption is reduced while taking adsorbents and antacids.
Adrenomimetics weaken the effect of terazosin.
With simultaneous use of terazosin and NSAIDs, a decrease in the antihypertensive effect is possible due to the suppression of the synthesis of prostaglandins and the retention of fluids and sodium ions.
Pregnancy and Lactation
Kornam can be used during pregnancy and during breastfeeding if the potential benefit to the mother outweighs the possible risk to the fetus or infant.
To prevent the development of orthostatic hypotension, treatment should begin with the appointment of Kornam at a dose of 1 mg / day. before bedtime, after which the patient should be in bed for 6-8 hours.
The risk of orthostatic hypotension ("first dose effect") is highest within 30-90 minutes after taking the drug and increased in patients simultaneously receiving beta-blockers and diuretics, with a decrease in BCC, a hypo-salt diet, and also with the resumption of drug treatment after break (several days).
In the case of a temporary cessation of treatment, resume therapy with the same dose. During treatment, the level of prostate specific antigen does not change. Before starting therapy for benign prostatic hyperplasia, it is necessary to exclude prostate cancer.
The patient must be informed about the increased risk of orthostatic hypotension in the use of alcohol, prolonged standing or exercise, as well as during hot weather.
Within 12 hours after taking the first dose, after increasing the dose or interrupting therapy, it is not recommended to engage in potentially hazardous activities that require increased attention and speed of psychomotor reactions.
Symptoms: pronounced decrease in blood pressure, impaired coordination of movements, fainting.
Treatment: It is necessary to put the patient down by lowering the head end of the bed. If necessary, appoint hypertensive agents, IV the introduction of fluid. Hemodialysis is not effective.
- Brand name: Kornam
- Active ingredient: Terazosin
- Dosage form: Pills.
- Manufacturer: Sandoz
- Country of Origin: Switzerland
- Effect of finasteride and/or terazosin on serum PSA: Results of VA cooperative study #359
- Transdermal drug delivery using electroporation. II. Factors influencing skin reversibility in electroporative delivery of terazosin hydrochloride in hairless rats
- Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-β expression in benign prostatic hyperplasia
- Identification, preparation, and characterization of several polymorphs and solvates of terazosin hydrochloride
- Effect of terazosin on urine storage and voiding in the aging male with prostatism
- Lanthanide recognition: A Ho3+ potentiometric membrane sensor as a probe for determination of terazosin
- Fluorescent quantification of terazosin hydrochloride content in human plasma and tablets using second-order calibration based on both parallel factor analysis and alternating penalty trilinear decomposition
- Direct high-performance liquid chromatography enantioseparation of terazosin on an immobilised polysaccharide-based chiral stationary phase under polar organic and reversed-phase conditions
- Validated specific HPLC methods for determination of prazosin, terazosin and doxazosin in the presence of degradation products formed under ICH-recommended stress conditions
- Study of the interaction between terazosin and serum albumin: Synchronous fluorescence determination of terazosin
- Enantioselective determination of terazosin in human plasma by normal phase high-performance liquid chromatography–electrospray mass spectrometry
- High-performance liquid chromatographic measurement of prazosin and terazosin in biological fluids
- Rapid and sensitive analysis of terazosin in plasma, peritoneal dialysis solution, and urine using high-performance liquid chromatography with fluorescence detection
- Determination of terazosin in human plasma, using high-performance liquid chromatography with fluorescence detection
- Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics
- Differential vascular α1-adrenoceptor antagonism by tamsulosin and terazosin
- Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: A short-term open, randomized multicenter study
- Magnetic resonance imaging and morphometric histologic analysis of prostate tissue composition in predicting the clinical outcome of terazosin therapy in benign prostatic hyperplasia
- Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects
- Clinical comparison of selective and non-selective &agr;1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses
- Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men
- The effectiveness of terazosin, an α1-blocker, on bladder neck obstruction as assessed by urodynamic hydraulic energy
- A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients
- Effects of intravenous and infravesical administration of suramin, terazosin and BMY 7378 on bladder instability in conscious rats with bladder outlet obstruction